Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | TK2 | O00142 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL787593 | 0.91 | SLC28A1 (0.65) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12718344 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL2722555 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL13497202 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL767986 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL10382149 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL14596596 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12296879 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL21078835 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL3437224 | 0.91 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113755416-B | Recombinant microorganism having novel synthetic pathway for producing beta-thymidine and method for producing beta-thymidine | 苏州华赛生物工程技术有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-113755416-A | Recombinant microorganism with novel synthetic pathway for producing beta-thymidine and method for producing beta-thymidine | 苏州华赛生物工程技术有限公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-101838696-B | For the pearl of high-throughput nucleic acid analysis | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-25 | — | — | CN | disclosed |
| CN-101845494-B | Miniaturized, high-throughput nucleic acid analysis | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-25 | — | — | CN | disclosed |
| CN-101418340-B | Diagnostic test for susceptibility to b-raf kinase inhibitors | HOFFMANN LA ROCHE | 2014-05-07 | — | — | CN | disclosed |
| EP-2434421-A2 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | The Regents of The University of California (US) | 2012-03-28 | — | — | EP | disclosed |
| CN-101845494-A | Miniaturized, high-throughput nucleic acid analysis | HOFFMANN LA ROCHE | 2010-09-29 | — | — | CN | disclosed |
| CN-101838696-A | The pearl that is used for high-throughput nucleic acid analysis | HOFFMANN LA ROCHE | 2010-09-22 | — | — | CN | disclosed |
| CN-101418340-A | The diagnostic detection of B-RAF kinase inhibitor susceptibility | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | CN | disclosed |
| CN-100385009-C | Method of preparing a guanosine-group compound and an intermediate thereof | YUKI GOSEI YAKUHIN KOGYO KK (JP) | 2008-04-30 | — | — | CN | disclosed |
| CN-100350052-C | Method of preparing a guanosine-group compound and an intermediate thereof | YUKI GOSEI YAKUHIN KOGYO KK (JP) | 2007-11-21 | — | — | CN | disclosed |
| CN-1821420-A | Method of preparing a guanosine-group compound and an intermediate thereof | YUKI GOSEI YAKUHIN KOGYO KK (JP) | 2006-08-23 | — | — | CN | disclosed |
| CN-1818074-A | Method of preparing a guanosine-group compound and an intermediate thereof | YUKI GOSEI YAKUHIN KOGYO KK (JP) | 2006-08-16 | — | — | CN | disclosed |
| CN-1818073-A | Method of preparing a guanosine-group compound and an intermediate thereof | YUKI GOSEI YAKUHIN KOGYO KK (JP) | 2006-08-16 | — | — | CN | disclosed |
| CN-1243833-C | Process for preparing guanosine-group compounds and intermediates thereof | ORGANIC SYNTHETIC PHARMACEUTIC (JP) | 2006-03-01 | — | — | CN | disclosed |
| CN-1320706-A | Process for preparing guanosine-group compounds and intermediates thereof | ORGANIC SYNTHETIC PHARMACEUTIC (JP) | 2001-11-07 | — | — | CN | disclosed |